Does perioperative systemic therapy represent the optimal therapeutic paradigm in organ-confined, muscle-invasive urothelial carcinoma?

Future Sci OA. 2021 Oct 28;7(9):FSO770. doi: 10.2144/fsoa-2021-0092. eCollection 2021 Oct.

Luca Scafuri^{1

2}, Antonella Sciarra³, Felice Crocetto⁴, Matteo Ferro⁵, Carlo Buonerba^{1

2}, Francesco Ugliano⁶, Germano Guerra⁶, Roberto Sanseverino⁷, Giuseppe Di Lorenzo^{1

2

6}

¹ Oncology Unit, Hospital 'Andrea Tortora,' ASL Salerno, Pagani, 84016, Italy.
² Associazione O.R.A., Somma Vesuviana, Naples, Italy.
³ Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli,' Naples, NA, 80131, Italy.
⁴ Department of Neurosciences, Reproductive Sciences & Odontostomatology, Federico II University, Naples, 80131, Italy.
⁵ Division of Urology, European Institute of Oncology (IEO), IRCCS, Milan, 20099, Italy.
⁶ Department of Medicine & Health Science, University of Molise, Campobasso, 86100, Italy.
⁷ Department of Urology, Umberto I Hospital, ASL Salerno, Nocera Inferiore, 84014, Italy.

No abstract available

Keywords: adjuvant therapy; bladder cancer; neoadjuvant therapy.

Publication types